常山药业
(300255)
| 流通市值：106.88亿 | | | 总市值：107.25亿 |
| 流通股本：9.16亿 | | | 总股本：9.19亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 294,318,791.37 | 1,410,439,649.66 | 1,139,615,425.99 | 820,374,969.65 |
| 营业收入 | 294,318,791.37 | 1,410,439,649.66 | 1,139,615,425.99 | 820,374,969.65 |
| 二、营业总成本 | 355,149,467.25 | 2,005,215,648.54 | 1,439,650,840.38 | 946,281,789.41 |
| 营业成本 | 259,321,388.72 | 1,093,062,444.69 | 784,467,890.22 | 507,703,256.44 |
| 税金及附加 | 2,874,375.07 | 21,069,268.5 | 17,339,727.38 | 13,289,900.84 |
| 销售费用 | 17,784,564.85 | 472,844,404.35 | 348,418,548.74 | 233,577,082.61 |
| 管理费用 | 35,926,076.74 | 166,472,603.01 | 112,623,023.81 | 75,170,333.03 |
| 研发费用 | 16,435,989.22 | 158,824,447.18 | 100,561,746.37 | 70,070,734.81 |
| 财务费用 | 22,807,072.65 | 92,942,480.81 | 76,239,903.86 | 46,470,481.68 |
| 其中:利息费用 | 18,896,073.87 | 96,413,978.88 | 77,386,645.94 | 48,707,093.22 |
| 其中:利息收入 | 385,859.98 | 1,841,254.86 | 1,418,143.65 | 1,154,309.82 |
| 加:投资收益 | - | 7,024.76 | - | - |
| 资产处置收益 | - | 7,001.33 | - | - |
| 资产减值损失(新) | - | -633,317,242.23 | -121,354,856.55 | -51,316,610.91 |
| 信用减值损失(新) | -848,407.98 | -25,924,208.51 | 422,670.77 | 1,237,000.43 |
| 其他收益 | 2,157,666.48 | 27,678,544.04 | 14,689,581.79 | 12,874,484.07 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -59,521,417.38 | -1,226,324,879.49 | -406,278,018.38 | -163,111,946.17 |
| 加:营业外收入 | 80,022.13 | 184,165.79 | 131,700.64 | 47,443.05 |
| 减:营业外支出 | 69,368.34 | 5,554,072.41 | 781,984.93 | 276,471.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -59,510,763.59 | -1,231,694,786.11 | -406,928,302.67 | -163,340,974.15 |
| 减:所得税费用 | 2,495,154.06 | 16,459,329.12 | -11,988,189.41 | -2,148,047.88 |
| 六、净利润 | -62,005,917.65 | -1,248,154,115.23 | -394,940,113.26 | -161,192,926.27 |
| 持续经营净利润 | -62,005,917.65 | -1,248,154,115.23 | -394,940,113.26 | -161,192,926.27 |
| 归属于母公司股东的净利润 | -61,665,097.94 | -1,240,210,952.88 | -388,330,627.87 | -155,878,327.3 |
| 少数股东损益 | -340,819.71 | -7,943,162.35 | -6,609,485.39 | -5,314,598.97 |
| (一)基本每股收益 | -0.07 | -1.35 | -0.42 | -0.17 |
| (二)稀释每股收益 | -0.07 | -1.35 | -0.42 | -0.17 |
| 八、其他综合收益 | -43,398.03 | -1,582,310.32 | -928,525.69 | -874,455.63 |
| 归属于母公司股东的其他综合收益 | -43,398.03 | -1,582,310.32 | -928,525.69 | -874,455.63 |
| 九、综合收益总额 | -62,049,315.68 | -1,249,736,425.55 | -395,868,638.95 | -162,067,381.9 |
| 归属于母公司股东的综合收益总额 | -61,708,495.97 | -1,241,793,263.2 | -389,259,153.56 | -156,752,782.93 |
| 归属于少数股东的综合收益总额 | -340,819.71 | -7,943,162.35 | -6,609,485.39 | -5,314,598.97 |
| 公告日期 | 2024-04-29 | 2024-04-29 | 2023-10-25 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |